Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae
Drug Delivery and Translational Research · 2025-05 · 15 (5) · 1739-1754
DOI: 10.1007/s13346-024-01708-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 16.09.2024. Verfasst von Ethan Watt und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Waterloo, Waterloo, ON, N2G 1C5, Canada. Hauptthemen laut MEDLINE: Streptolysins, Streptococcus pneumoniae, Anti-Bacterial Agents, Cholesterol. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Natural Sciences and Engineering Research Council of Canada, NanoMedicines Innovation Network.
Abstract (Originalsprache)
The bacterium Streptococcus pneumoniae has become a leading cause of meningitis, sepsis, and bacterial pneumonia worldwide, with increased prevalence of antibiotic-resistant serotypes serving to exacerbate the issue. The main factor responsible for colonization and immune response escape in pneumococcal infections is the secreted molecule pneumolysin, which is a subset within a family of related toxins that form transmembrane pores in biological membranes through cholesterol recognition and binding. The conserved activity and structure of pneumolysin between all observed S. pneumoniae serotypes, along with its requirement for pathogenicity, has made this molecule an attractive target for vaccination, diagnostic, and sequestration platforms, but not yet as a facilitative agent for therapeutic treatment. Consequently, the present work aimed to examine the impact of liposomal cholesterol content for pneumolysin-induced release of the encapsulated antimicrobial peptide nisin. It was determined that a cholesterol content above 45 mol% was necessary to facilitate interactions with both purified pneumolysin toxin and S. pneumoniae culture, demonstrated through enhanced nisin release and a reduction in hemolytic rates upon exposure of the toxin with cholesterol-rich vesicles. Antibacterial testing highlighted the ability of the developed platform to elicit a potent and specific bactericidal response in vitro against cultured S. pneumoniae when compared to a control strain, Staphylococcus epidermidis. It further improved viability of a fibroblast cell line upon S. pneumoniae challenge, outperforming free nisin via the synergistic impact of simultaneous bacterial clearance and pneumolysin neutralization. These findings collectively indicate that cholesterol-rich liposomes hold promise as a selective treatment platform against pneumococcal infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Waterloo, Waterloo, ON, N2G 1C5, Canada.
- School of Pharmacy, University of Waterloo, Waterloo, ON, N2G 1C5, Canada. emmanuel.ho@uwaterloo.ca.
- Waterloo Institute for Nanotechnology, University of Waterloo, Waterloo, ON, N2L 3G1, Canada. emmanuel.ho@uwaterloo.ca.
ORCID-Profile: Ethan Watt, Emmanuel A Ho
Förderung
- Natural Sciences and Engineering Research Council of Canada
- NanoMedicines Innovation Network
Zitieren
APA
Watt, E., Andriescu, I., & Ho, E. A. (2025). Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae. Drug Delivery and Translational Research, 15(5), 1739-1754. https://doi.org/10.1007/s13346-024-01708-5
Vancouver
Watt E, Andriescu I, Ho EA. Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae. Drug Delivery and Translational Research. 2025;15(5):1739-1754. doi:10.1007/s13346-024-01708-5
BibTeX
@article{Watt2025,
author = {Watt, Ethan and Andriescu, Ilinca and Ho, Emmanuel A},
title = {Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae},
journal = {Drug Delivery and Translational Research},
year = {2025},
volume = {15},
number = {5},
pages = {1739--1754},
doi = {10.1007/s13346-024-01708-5}
}
EUVIMED